Page last updated: 2024-10-24

carvedilol and Hepatic Encephalopathy

carvedilol has been researched along with Hepatic Encephalopathy in 5 studies

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research Excerpts

ExcerptRelevanceReference
"Carvedilol treatment decreased the brain levels of oxidative stress markers and induced Nrf2/HO-1 pathway."5.72Carvedilol attenuates brain damage in mice with hepatic encephalopathy. ( Amirshahrokhi, K; Niapour, A, 2022)
" First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome."5.41Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023)
"Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e."2.58[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018)
"Carvedilol treatment decreased the brain levels of oxidative stress markers and induced Nrf2/HO-1 pathway."1.72Carvedilol attenuates brain damage in mice with hepatic encephalopathy. ( Amirshahrokhi, K; Niapour, A, 2022)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Amirshahrokhi, K1
Niapour, A1
Tapper, EB1
Parikh, ND1
Karkmann, K1
Piecha, F1
Rünzi, AC1
Schulz, L1
von Wulffen, M1
Benten, D1
Kluwe, J1
Wege, H1
Villanueva, C1
Albillos, A1
Genescà, J1
Garcia-Pagan, JC1
Calleja, JL1
Aracil, C1
Bañares, R1
Morillas, RM1
Poca, M1
Peñas, B1
Augustin, S1
Abraldes, JG1
Alvarado, E1
Torres, F1
Bosch, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485]1,000 participants (Actual)Observational2022-01-01Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396]Phase 4201 participants (Actual)Interventional2010-01-28Completed
CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477]1,000 participants (Anticipated)Observational2021-07-16Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for carvedilol and Hepatic Encephalopathy

ArticleYear
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
    JAMA, 2023, 05-09, Volume: 329, Issue:18

    Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc

2023
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
    Zeitschrift fur Gastroenterologie, 2018, Volume: 56, Issue:1

    Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop

2018

Trials

1 trial available for carvedilol and Hepatic Encephalopathy

ArticleYear
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet (London, England), 2019, Apr-20, Volume: 393, Issue:10181

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me

2019

Other Studies

2 other studies available for carvedilol and Hepatic Encephalopathy

ArticleYear
Carvedilol attenuates brain damage in mice with hepatic encephalopathy.
    International immunopharmacology, 2022, Volume: 111

    Topics: Animals; Brain; Brain Injuries; Carvedilol; Hepatic Encephalopathy; Mice; NF-kappa B; Oxidative Stre

2022
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
    Clinical and molecular hepatology, 2020, Volume: 26, Issue:2

    Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G

2020